-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Checkpoint Blockade in Lymphoma

Program: Education Program
Session: Contemporary Therapy of Lymphoma
Saturday, December 5, 2015, 2:00 PM-3:30 PM
Chapin Theater (W320), Level 3 (Orange County Convention Center)
Sunday, December 6, 2015, 9:30 AM-11:00 AM
Hall D, Level 2 (Orange County Convention Center)

Philippe Armand, MD, PhD

Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Disclosures: Armand: Infinity Pharmaceuticals: Consultancy ; Merck: Consultancy , Research Funding ; Bristol-Myers Squibb: Research Funding . Off Label Use: Nivolumab, pembrolizumab, pidilizumab in lymphoma.

See more of: Contemporary Therapy of Lymphoma
See more of: Education Program
Previous Presentation | Next Presentation >>